LCM
TRAW icon

Lynx1 Capital Management’s Traws Pharma TRAW Stock Holding History

Lynx1 Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$472K Buy
559,470
+544,392
+3,611% +$750K 0.05% 16
2026
Q1 		$27.6K Buy
+15,078
New +$28.3K ﹤0.01% 23

Other funds holding TRAW

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Lynx1 Capital Management's TRAW Position: Q2 2026 in Review

Lynx1 Capital Management increased its Traws Pharma (TRAW) stake by 3,611% in Q2 2026, buying an estimated $750K and bringing the position to 559,470 shares worth $472K. The position accounts for 0.05% of the portfolio, ranked #16.

Lynx1 Capital Management first reported a position in TRAW in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • Lynx1 Capital Management held 559,470 shares of Traws Pharma worth $472K as of Q2 2026.
  • Lynx1 Capital Management bought 544,392 Traws Pharma shares in Q2 2026, an estimated $750K.
  • Traws Pharma made up 0.05% of Lynx1 Capital Management's portfolio in Q2 2026, its #16 holding.
  • Lynx1 Capital Management first reported a position in Traws Pharma in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.